The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer

Keyphrases

• Non-melanoma Skin Cancer 100%
• Mutagenesis 100%
• Tumor Protein p53 (TP53) 100%
• MDM2 Polymorphism 100%
• TP53 Polymorphism 100%
• Confidence Interval 66%
• Tumor 33%
• Basal Cell Carcinoma 33%
• TP53 mutation 33%
• Murine Double Minute 2 (MDM2) 33%
• TP53 Alterations 33%
• Gene-specific 16%
• Oncogenesis 16%
• Polymorphism 16%
• Genotype 16%
• Regulatory Molecules 16%
• Immunohistochemical Staining 16%
• Arginine 16%
• Oncogene 16%
• Protein Level 16%
• Proline 16%
• Squamous Cell Carcinoma (SqCC) 16%
• Odds Ratio 16%
• Cellular Response 16%
• P53 Protein 16%
• Negatively Regulate 16%
• Specific mutation 16%
• Genotype P 16%
• Population-based Case-control Study 16%
• Functional Polymorphism 16%
• Skin Cancer Risk 16%
• Radiation mutagenesis 16%
• Arg72Pro 16%
• MDM2 SNP309 16%

Biochemistry, Genetics and Molecular Biology

• Mutagenesis 100%
• Allele 100%
• Genotyping 66%
• P53 66%
• Oncogene 33%
• Case-Control Study 33%
• Proline 33%
• Arginine 33%
• Ultraviolet Radiation 33%
• Carcinogenesis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mutagenesis 100%
• Non Melanoma Skin Cancer 100%
• Basal Cell Carcinoma 33%
• Protein P53 33%
• Neoplasm 33%
• Skin Cancer 16%
• Case-Control Study 16%
• Ultraviolet Radiation 16%
• Squamous Cell Carcinoma 16%
• Arginine 16%
• Carcinogenesis 16%
• Proline 16%